PDS Biotechnology Corp financial data

Symbol
PDSB on Nasdaq
Location
Princeton, NJ
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 13 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 248 % -35.3%
Debt-to-equity 151 % +40.2%
Return On Equity -209 % -49.7%
Return On Assets -83.3 % -23.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 49M shares +30.9%
Common Stock, Shares, Outstanding 47.7M shares +29.6%
Entity Public Float 104M USD -30.1%
Common Stock, Value, Issued 15.7K USD +29.6%
Weighted Average Number of Shares Outstanding, Basic 46.9M shares +27.3%
Weighted Average Number of Shares Outstanding, Diluted 46.9M shares +27.3%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 19.2M USD -24.9%
General and Administrative Expense 13.1M USD -5.67%
Operating Income (Loss) -32.2M USD +18.1%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -36.1M USD +16%
Income Tax Expense (Benefit) -270K USD
Net Income (Loss) Attributable to Parent -34.9M USD +14%
Earnings Per Share, Basic 0 USD/shares +29.9%
Earnings Per Share, Diluted 0 USD/shares +29.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 26.2M USD -47.3%
Assets, Current 27.9M USD -46.5%
Property, Plant and Equipment, Net 126K USD -14.8%
Operating Lease, Right-of-Use Asset 0 USD -100%
Assets 34.7M USD -33.8%
Accounts Payable, Current 5.18M USD +298%
Accrued Liabilities, Current 2.1M USD -53%
Liabilities, Current 13.3M USD -27.3%
Operating Lease, Liability, Noncurrent 0 USD
Liabilities 25.3M USD -17.1%
Retained Earnings (Accumulated Deficit) -209M USD -20%
Stockholders' Equity Attributable to Parent 9.45M USD -57%
Liabilities and Equity 34.7M USD -33.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -9.03M USD +9.12%
Net Cash Provided by (Used in) Financing Activities 7.32M USD -63.4%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 47.7M shares +29.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 26.2M USD -47.3%
Interest Paid, Excluding Capitalized Interest, Operating Activities 694K USD -40.9%
Deferred Tax Assets, Valuation Allowance 64.7M USD +14.1%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 64.7M USD +14.1%
Operating Lease, Liability 59.7K USD -84.9%
Depreciation 5.46K USD +15.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -34.9M USD +14%
Lessee, Operating Lease, Liability, to be Paid 60.3K USD -85.6%
Property, Plant and Equipment, Gross 296K USD +10.9%
Operating Lease, Liability, Current 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year Two 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year One 0 USD -100%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 683 USD -97%
Lessee, Operating Lease, Liability, to be Paid, Year Three 0 USD
Current Income Tax Expense (Benefit) 0 USD
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Operating Lease, Payments 0 USD -100%
Additional Paid in Capital 218M USD +11.4%
Deferred Tax Assets, Net of Valuation Allowance 46.6K USD -17.9%
Share-based Payment Arrangement, Expense 4.59M USD -29.9%
Interest Expense 4.41M USD +93.3%